Cereno Scientific reports an investigator-initiated patient case study from the ongoing Phase II study of CS1 in PAH
Cereno Scientific (Nasdaq First North: CRNO B), a company developing innovative treatments for common and rare cardiovascular disease, today announced data received from a patient case study initiated by an investigator on the first patient having completed the Phase II study of CS1 in the rare disease pulmonary arterial hypertension (PAH) at the site. The case study is based on one patient and was performed to control the utility of CardioMEMS™ HF System (Abbott, Inc.), an innovative technology used to daily monitor pulmonary pressure and other cardiopulmonary function in patients in the